Celldex Therapeutics. has been granted a patent for methods involving antibodies that target the KIT receptor tyrosine kinase. These methods aim to manage, treat, or prevent eosinophil and mast cell-related disorders, including conditions like neuromyelitis optica and multiple sclerosis, by administering specific monoclonal antibodies. GlobalData’s report on Celldex Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Celldex Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Celldex Therapeutics's grant share as of June 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for treating eosinophil and mast cell disorders
The granted patent US11987626B2 outlines a method for protecting against, treating, or managing eosinophil-related disorders in the gastrointestinal tract, particularly those triggered by allergens. The method involves administering a therapeutically effective amount of a monoclonal antibody that specifically targets the human KIT receptor, as defined by SEQ ID NO: 1. The claims detail the structural requirements of the antibody, including specific variable regions for both the light and heavy chains, which are characterized by defined complementarity-determining regions (CDRs) identified by SEQ ID NOs: 2-7. The method is applicable to both adults and children suffering from eosinophil-related disorders.
Further claims specify that the antibody may be humanized and can include various sequences for the light and heavy chain variable regions, allowing for flexibility in the design of the therapeutic agent. The patent emphasizes the importance of the antibody's specificity to the human KIT receptor, which is crucial for its therapeutic efficacy. Overall, the claims provide a comprehensive framework for the development of targeted monoclonal antibody therapies aimed at managing eosinophil-related gastrointestinal disorders.
To know more about GlobalData’s detailed insights on Celldex Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
